2022
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)
Lee S, Ma C, Zhang S, Ou FS, Bainter TM, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Kindler H, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS. Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). The Oncologist 2022, 27: e494-e505. PMID: 35641198, PMCID: PMC9177101, DOI: 10.1093/oncolo/oyab070.Peer-Reviewed Original ResearchConceptsStage III colon cancerRecurrence-free survivalOverall survivalColon cancerCALGB 89803Marital statusAdjuvant chemotherapy trialsColorectal cancer outcomesColon cancer mortalityTime of enrollmentLiving arrangementsChemotherapy trialsSocial support servicesSurvival outcomesCancer mortalityPatient populationCancer outcomesClinical trialsSpouse/partnerWorse outcomesCancer recurrenceNursing homesPatientsSecondary analysisCancerDiet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)
Cheng E, Ou FS, Ma C, Spiegelman D, Zhang S, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Brown JC, Ng K, Gross CP, Meyerhardt JA, Fuchs CS. Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). Journal Of Clinical Oncology 2022, 40: 740-751. PMID: 34995084, PMCID: PMC8887946, DOI: 10.1200/jco.21.01784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsDietFemaleFollow-Up StudiesHumansLife StyleMaleMiddle AgedModels, StatisticalMulticenter Studies as TopicNeoplasm Recurrence, LocalNomogramsPrognosisRandomized Controlled Trials as TopicRisk FactorsSurvival RateConceptsStage III colon cancerDisease-free survivalLifestyle factorsSelf-reported dietPathologic featuresColon cancerPathologic characteristicsMultivariable Cox proportional hazards regressionCox proportional hazards regressionAdjuvant chemotherapy trialsProportional hazards regressionPredictive survivalChemotherapy trialsDFS eventsOverall survivalSurvival prediction modelHazards regressionSurvival outcomesVisual nomogramLifestyle habitsPatient outcomesCancer recurrenceLifestyle exposuresPatientsCancer
2021
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)
Lee S, Zhang S, Ma C, Ou FS, Wolfe EG, Ogino S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectrum 2021, 5: pkab034-. PMID: 34104867, PMCID: PMC8178799, DOI: 10.1093/jncics/pkab034.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlack PeopleChemotherapy, AdjuvantColonic NeoplasmsConfidence IntervalsDietDisease-Free SurvivalFemaleHealth Services AccessibilityHumansIncomeLife StyleMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingProportional Hazards ModelsProspective StudiesWhite PeopleConceptsAdjusted hazard ratioDisease-free survivalRecurrence-free survivalColon cancer patientsHome zip codeMedian household incomeCALGB 89803Hazard ratioOverall survivalCancer patientsStage III colon cancer patientsStage III colon cancerPatient's home zip codeAdjuvant chemotherapy trialsStudy of patientsColon cancer outcomesHealth care accessChemotherapy trialsStudy enrollmentBlack patientsCancer outcomesLifestyle factorsLowest quartileObservational studyPatients
2008
Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer
Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer. Journal Of Clinical Oncology 2008, 26: 4679-4683. PMID: 18662965, DOI: 10.1200/jco.2008.17.2544.Peer-Reviewed Original ResearchConceptsDisease-free survivalER-positive breast cancerAdjuvant chemotherapy trialsProportion of patientsBreast cancerChemotherapy trialsRS patientsEstrogen receptor-positive breast cancerRandomized adjuvant chemotherapy trialReceptor-positive breast cancerFuture adjuvant studiesProportion of casesTwo-arm clinical trialChemotherapy decreasesMolecular diagnostic testsAdjuvant chemotherapyEndocrine therapyAdjuvant studiesDisease subsetsPositive cancersClinical trialsDFS estimatesRisk groupsEstrogen receptorMolecular subtypesEstrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. Journal Of Clinical Oncology 2008, 26: 2636-2643. PMID: 18509176, DOI: 10.1200/jco.2007.14.9146.Peer-Reviewed Original ResearchConceptsER-negative patientsER-positive patientsRisk of recurrenceDocetaxel therapyER expressionER statusPooled analysisBreast cancerNode-positive breast cancerCox proportional hazards modelAdjuvant chemotherapy trialsDisease-free survivalEfficacy of docetaxelEstrogen receptor expressionPositive breast cancerRisk of deathRandomized clinical trialsProportional hazards modelAdjuvant chemotherapyAdjuvant docetaxelChemotherapy trialsOverall survivalDocetaxel efficacyRandomized trialsClinical variables
1993
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E, Kurtzberg J, Bast R, Jones R, Shpall E. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Journal Of Clinical Oncology 1993, 11: 1132-43. PMID: 8501500, DOI: 10.1200/jco.1993.11.6.1132.Peer-Reviewed Original ResearchConceptsAutologous bone marrow supportPrimary breast cancerHigh-risk primary breast cancerBone marrow supportEvent-free survivalBreast cancerMarrow supportLymph nodesActuarial event-free survivalMore axillary lymph nodesHigh-dose consolidationIIIB breast cancerStandard-dose cyclophosphamideTherapy-related mortalityAdjuvant chemotherapy trialsHigh-dose cyclophosphamideAxillary lymph nodesHigh-dose chemotherapyMore lymph nodesAdjuvant chemotherapy treatmentAdjuvant therapyChemotherapy trialsStudy patientsConcurrent cancerStage IIA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply